Toxicity testing: The search for an in vitro alternative to animal testing

British Journal of Biomedical Science

Volumn 66, Issue 3, 2009, Pages 160-165

  May, Jennifer E ^a   Xu, J ^a   Morse, H R ^a   Avent, N D ^a   Donaldson, C ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

Animal testing alternatives; Cytochrome P 450 enzyme system; Drug toxicity; Prodrugs

Indexed keywords

CALCIUM; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DACARBAZINE; DNA; DRUG METABOLITE; ETOPOSIDE; FLUTAMIDE; LIVER EXTRACT; PACLITAXEL; PRODRUG; TAMOXIFEN; TEGAFUR; TGN 1412; TISSUE EXTRACT; VINCRISTINE;

ANIMAL TESTING ALTERNATIVE; APOPTOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CALCIUM CELL LEVEL; CELL ADHESION; CELL COUNT; CLINICAL TRIAL; COCULTURE; COLORECTAL CANCER; COST; DNA REPAIR; DOSE CALCULATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; LD 50; LEUKEMIA; LIVER CELL; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; SPHEROID CELL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TESTIS CANCER; TOXICITY TESTING;

ANIMALIA;

EID: 71049135325     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2009.11730265     Document Type: Review

References (34)

1. OECD/OCDE 420 Guideline Document. OECD guideline for testing of chemicals. Acute oral toxicity - fixed-dose procedure 2001. http://iccvam.niehs. nih.gov/SuppDocs/FedDocs/OECD/ OECD-GL420.pdf (accessed 21 January 2009).
2. OECD Guidelines for the Testing of Chemicals. Summary of considerations in the report from the OECD expert groups on short-term and long-term toxicology 1979. http://oberon.sourceoecd.org/vl=335656/cl=12/nw=1/rpsv/ij/oecdjournals/ 1607310x/v1n4/s1/p1 (accessed 21 January 2009).
3. Ukelis U, Kramer PJ, Olejniczak K, Mueller SO. Replacement of in vivo acute oral toxidty studies by in vitro cytotoxidty methods: opportunities, limits and regulatory status. Regul Toxicol Pharmacol 2008; 51: 108-118
4. Russell WMS, Burch RL. The principle of humane experimental technique. London, 1959. http://altweb.jhsph.edu/publications/humane-exp/chap2a.htm (accessed 21 January 2009).
5. Home Office. Statistics of scientific procedures on living animals (UK) 2007. http://scienceandresearch.homeoffice.gov.uk/animal-research/publications- and-reference/statistics/ (accessed 22 September 2008).
6. Robinson S, Delongeas J, Donald E et al. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxidty studies in pharmaceutical drug development. Regul Toxicol Pharmacol 2008; 50: 345-352
7. Price PS, Keenan RE, Swartout JC. Characterising interspedes uncertainty using data from studies of anti-neoplastic agents in animals and humans. Toxicol Appl Pharmacol 2008; 233 (1): 64-70.
8. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028
9. Medicines and Healthcare products Regulatory Agency. Investigations into adverse incidents during clinical trials of TGN1412 2006. www.mhra.gov.uk/ NewsCentre/Pressreleases/CON2023822 (accessed 22 September 2008).
10. Olson H, Betton G, Robinson D et al. Concordance of the toxidty of pharmaceuticals in humans and animals. Regul Toxicol Pharmacol 2000; 32: 56-67. (Pubitemid 30764600)
11. McFayden MCE, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004; 3 (3): 363-371
12. van Schaik RHN. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23: 513-522 (Pubitemid 43162470)
13. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriquez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526. (Pubitemid 350116943)
14. Lin HJ. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006; 23 (6): 1089-1116
15. Freeman JL, Perry GH, Feuk L et al. Copy number variation: new insights in genome diversity. Genome Res 2006; 16: 949-961 (Pubitemid 44162254)
16. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1563-1570
17. Brandon EFA, Raap CD, Meijerman I, Bejnen JH, Schellens JHM. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003; 189: 233-246 (Pubitemid 36677534)
18. Waxman DJ, Morrissey JJ, Naik S, Jauregui HO. Phenobarbital induction of cytochromes P-450. High-level long-term responsiveness of primary rat hepatocyte cultures to drug induction, and glucocorticoid dependence of the phenobarbital response. Biochem J 1990; 271: 113-119
19. Deutsch WA, Kukreja A, Shane B, Hedge V. Phenobarbital, oxazepam and Wyeth 14,643 cause DNA damage as measured by the Comet assay. Mutagenesis 2001; 16 (5): 439-442 (Pubitemid 32894729)
20. Afsharian P, Terelius Y, Hassan Z, Nilsson C, Lundgren S, Hassan M. The effect of repeated administration of cyclophosphamide P450 2B in rats. Clin Cancer Res 2007; 13 (14): 4218-4224
21. O'Brien PJ, Irwin W, Diaz D et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006; 80: 580-604. (Pubitemid 44214526)
22. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-616 (Pubitemid 10213918)
23. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-498
24. Hewitt NJ, Hewitt P. Phase I and II enzyme characterisation of two sources of HepG2 cell lines. Xenobiotica 2004; 34 (3): 243-256 (Pubitemid 38478893)
25. Wilkening S, Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol 2003; 17 (4): 207-213 (Pubitemid 36974720)
26. Brandon EFA, Bosch TM, Deene MJ et al. Validation of in vitro cell models used in drug metabolism and transport studies: genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon cardnoma (CaCo-2, LS180) cell lines. Toxicol Appl Pharmacol 2006; 211: 1-10.
27. Fabre N, Arrivet E, Trancard J et al. A new hepatoma cell line for toxidty testing at repeated doses. Cell Biol Toxicol 2003; 19: 71-82. (Pubitemid 36560293)
28. Gruber HE, Hartley EN Jr. Human disc cells in monolayer vs. 3D culture: cell shape, division and matrix formation. BMC Musculoskelet Disord 2000; 1: 1.
29. Li C, Tian T, Nan K et al. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep 2008; 20 (6): 1465-1471
30. Xu J, Ma M, Purcell WM. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and enzyme release as cytotoxic markers. Toxicol Appl Pharmacol 2003; 189: 100-111
31. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 1995; 330: 115-181
32. Ku WW, Bigger A, Brambilla G et al. Strategy for genotoxidty testing - metabolic considerations. Mutat Res 2007; 627: 59-77.
33. Ringdén O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 2005; 113: 813-830 (Pubitemid 43934223)
34. Li AP, Bode C, Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxidty: comparative cytotoxidty of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem Biol Interact 2004; 150: 129-136